Second-Line Cabozantinib Effective in RAI-Refractory DTC
October 21st 2015
The oral multikinase inhibitor cabozantinib showed promise as a second- or third-line therapy in patients with advanced radioactive iodine-refractory differentiated thyroid cancer.